Quantitative 177Lu-DOTATATE SPECT/CT is predictive of 6-month PRRT morphological response in midgut neuroendocrine tumors: a pilot study

Abstract Background peptide receptor radionuclide therapy with 177Lu-DOTATATE has become an established second-line treatment for patients with advanced small intestine neuroendocrine tumors (siNET). Treatment efficacy is assessed several months after the end of treatment and is based on RECIST crit...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Iness Megherbi, Christopher Hoog, Marine Perrier, Hedia Brixi, Guillaume Cadiot, Christine Hoeffel-Fornes, David Morland
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	SpringerOpen 2025-05-01
Serie:	EJNMMI Research
Soggetti:	Neuroendocrine tumors Lutetium Lu 177 dotatate Single photon emission computerized tomography
Accesso online:	https://doi.org/10.1186/s13550-025-01250-6
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!